Related Experiment Video
Updated: Mar 8, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer]
Zsófia Küronya1, Krisztina Bíró1, Fruzsina Gyergyay1
1"C" Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet Budapest, Ráth György u. 7-9., 1122.
Abstract:
In the past six years, five new drugs have been approved by the FDA for the treatment of metastatic castrate-resistant prostate cancer. While the disease itself still remains incurable, the sequential use of these drugs can significantly prolong survival while maintaining good quality of life. Research from the past decade made it clear that androgen receptor-mediated processes play a central part in the progression of the disease. Hormonal mechanisms related to androgen-receptors can remain active until late stages of the disease. A deeper understanding of these mechanisms has led to the introduction of new endocrine therapies, which resulted in a change of the nomenclature. The identification and remodelling of androgen receptor mutations that are responsible for primary and secondary resistance developing during the new therapies can pave the way to new and more efficient androgen receptor inhibitor treatments. The aim of the review is to present the pathophysiology of the androgen receptor signaling axis at the receptor level, to review FDA-approved drugs and to draw attention to the most promising developments in the treatment of this disease. Orv. Hetil., 2017, 158(2), 42-49.
Insights
New FDA-approved drugs offer prolonged survival for metastatic castrate-resistant prostate cancer patients. Understanding androgen receptor pathways is key to developing more effective androgen receptor inhibitor treatments.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Metastatic castrate-resistant prostate cancer (mCRPC) remains incurable despite recent therapeutic advances.
- Androgen receptor (AR)-mediated signaling is crucial in mCRPC progression, even in late stages.
- Recent research has elucidated AR pathways, leading to new nomenclature and endocrine therapies.
Purpose of the Study:
- To review the pathophysiology of the AR signaling axis at the receptor level.
- To provide an overview of FDA-approved drugs for mCRPC.
- To highlight promising future developments in mCRPC treatment.
Main Methods:
- Review of current literature on prostate cancer pathophysiology and treatment.
- Analysis of FDA-approved drugs for mCRPC.
- Discussion of emerging therapeutic strategies targeting AR mutations.
Main Results:
- Five new drugs have been approved by the FDA for mCRPC in the last six years.
- Sequential drug use can extend survival and maintain quality of life in mCRPC patients.
- Understanding AR mutations is critical for overcoming resistance to current therapies.
Conclusions:
- While mCRPC is not curable, advanced understanding of AR signaling has led to improved treatments.
- New endocrine therapies targeting AR pathways offer significant benefits for mCRPC patients.
- Further research into AR mutations will drive the development of next-generation AR inhibitors.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:20Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
02:38Mitogens and the Cell Cycle